- Lilly, with new data, to seek FDA approval of obesity drug retatrutideThe new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.BioPharma Dive · 5d ago↗ source
- STAT+: What’s in the last-minute flurry of health care bills?Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior authorization top the list.STAT · 5d ago↗ source
- FDA panel confronting peptide controversyToday's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."STAT · 5d ago↗ source